The treatment of chronic hepatitis B: Focus on adefovir-like antivirals

Several options for the treatment of hepatitis B have been licensed in the last years: interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine. In addition tenofovir has been licensed in the EU and is expected to be licensed in the USA in 2008. The antivirals can be divide...

Descripción completa

Detalles Bibliográficos
Autor principal: Tillmann, Hans Ludger
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621388/
https://www.ncbi.nlm.nih.gov/pubmed/19209262
_version_ 1782163404669059072
author Tillmann, Hans Ludger
author_facet Tillmann, Hans Ludger
author_sort Tillmann, Hans Ludger
collection PubMed
description Several options for the treatment of hepatitis B have been licensed in the last years: interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine. In addition tenofovir has been licensed in the EU and is expected to be licensed in the USA in 2008. The antivirals can be divided into “lamivudine-like” and “adefovir-like”, which clinically differ in their capacity to induce “YMDD” mutants, which are the hallmark of lamivudine resistance. The differing resistance profile makes them good combination partners, even in the absence of synergy in antiviral potency.
format Text
id pubmed-2621388
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26213882009-02-10 The treatment of chronic hepatitis B: Focus on adefovir-like antivirals Tillmann, Hans Ludger Ther Clin Risk Manag Review Several options for the treatment of hepatitis B have been licensed in the last years: interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine. In addition tenofovir has been licensed in the EU and is expected to be licensed in the USA in 2008. The antivirals can be divided into “lamivudine-like” and “adefovir-like”, which clinically differ in their capacity to induce “YMDD” mutants, which are the hallmark of lamivudine resistance. The differing resistance profile makes them good combination partners, even in the absence of synergy in antiviral potency. Dove Medical Press 2008-08 2008-08 /pmc/articles/PMC2621388/ /pubmed/19209262 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Tillmann, Hans Ludger
The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
title The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
title_full The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
title_fullStr The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
title_full_unstemmed The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
title_short The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
title_sort treatment of chronic hepatitis b: focus on adefovir-like antivirals
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621388/
https://www.ncbi.nlm.nih.gov/pubmed/19209262
work_keys_str_mv AT tillmannhansludger thetreatmentofchronichepatitisbfocusonadefovirlikeantivirals
AT tillmannhansludger treatmentofchronichepatitisbfocusonadefovirlikeantivirals

Ejemplares similares